MARKETRESEARCH
Uploaded on Feb 9, 2024
Category
Health & Medicine
According to the latest research report by IMARC Group, The global glaucoma therapeutics market size reached US$ 7.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.6% during 2024-2032. More Info:- https://www.imarcgroup.com/glaucoma-therapeutics-market
Category
Health & Medicine
Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industry Players 2024-32
Global Glaucoma
Therapeutics Market
Research and Forecast
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved
About IMARC Group
In ternat ional Market Analys is Research and Consul t ing Group is a leading adv iser on management
s t rategy and market research wor ldwide. We par tner wi th c l ients in a l l regions and indust ry
vert ica ls to ident i fy thei r h ighest -value oppor tuni t ies, address thei r most cr i t ica l chal lenges, and
t ransform thei r bus inesses.
IMARC’s in format ion products inc lude major market , sc ient i f ic , economic and technological
developments for bus iness leaders in pharmaceut ica l , indust r ia l , and h igh technology
organizat ions. Market forecasts and indust ry analys is for b iotechnology, advanced mater ia ls ,
chemicals , food and beverage, t ravel and tour ism, nanotechnology and novel process ing methods
are at the top of the company’s exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight in to the dynamics o f companies and
markets wi th c lose cooperat ion at a l l levels of the c l ient organizat ion. This ensures that our c l ients
achieve unmatchable compet i t ive advantage, bui ld more pro f ic ient organizat ions, and secure
las t ing resul ts .
A cc o r d i ng t o t h e l a te s t r e po r t b y IM A R C G r o up , t i t l e d " G l a u c o m a T h e r a p e u t i c s
Ma r k e t : G l o b a l In d u s t r y T r e n d s , S h a r e , S i ze , G r o w t h , O p p o r t u n i ty a n d F o r e c a s t
20 2 4 - 2 03 2 , " t h e g l ob a l g l a u c o ma t he r a p eu t i c s m a r ke t s i ze r ea c h e d U S $ 7 .9 B i l l i on i n
20 2 3 .
G l a u c o ma i s a n o cu l a r d i s o rd e r t h a t d am a g es t h e o p t i c n e r v e o f t h e pa t i e n t . T h e
Report s t r u c t u r a l c h a n g es i n t h e o p t i c n e rv e s a r e u su a l l y c a u s ed b y t h e a b n o r ma l l y h i g h
i n t r a o c u l a r p re s s u re ( IO P ) d u e to t h e e x t ra b u i l d - u p o f f l u i d i n t h e f r on t p a r t o f t h e
ey e s . T h i s c o n d i t i on ca n o f t e n l ea d to v i s i o n l o s s a n d p e rm a ne n t b l i n d n e ss i n
Highlight and p r o g r e s s i v e c as e s .
N um e r ou s m e d i c a t i o n s a nd t h e ra p i e s a r e p r e s c r i b e d t o pa t i e n t s w i t h g l a u c om a i n o r d e r
Description t o av o i d c o m p l e t e v i s i o n l o ss . E y e d r o p s t ha t b e l o n g t o t h e c l a s s o f b e t a - b l o c k e r s , a l p ha a g o n i s t s , p r o s ta g l a n d i ns an d c h o l i ne r g i c a re u s u a l l y p r e s c r i be d t o r ed u c e t h e
p r o d u c t i o n o f f l u i d i n t he e y e s . T h e s e d r o p s c a n t h e n be f o l l o w e d b y co n v e n t i o n a l o r
l a se r s u r g e r i e s f o r e f f e c t i v e re s u l t s . I n s e ve r a l c a s e s , a c o mb i n a t i on o f b o th
ap p r o a ch e s i s u t i l i z e d f o r t he t r e a t m e n t o f g l a u c o ma .
R eq u e s t f o r a P D F sa m p le o f th i s r ep o r t :
h t t p s : / /w w w . i ma r c g r o u p . co m / g l a uc o m a- t h e ra p e u t i c s - m a rk e t / re q u e s t s a m p l e
Report Description
G lo b a l G l a u c o m a T h e r a p e u t ic s M a r k e t T r e n d s :
T h e m a r k e t i s p r i m a r i l y d r i v e n b y t h e i n c r e a s i n g o c c u r r e n c e o f g l a u c o m a o n t h e g l o b a l l e v e l . T h i s c a n b e a t t r i b u t e d t o t h e r i s i n g
n u m b e r o f p a t i e n t s w h o h a v e d i a b e t e s d u e t o t h e i r s h i f t i n g l i f e s t y l e p a t t e r n s a n d a l a c k o f p h y s i c a l a c t i v i t i e s . T h i s , a l o n g w i t h t h e
i n c r e a s i n g g e r i a t r i c p o p u l a t i o n t h a t i s m o r e s u s c e p t i b l e t o c h r o n i c o c u l a r d i s o r d e r s , i s p r o v i d i n g a t h r u s t t o t h e m a r k e t g r o w t h .
A l o n g w i t h t h i s , t h e r e h a s b e e n a g r o w i n g p r e f e r e n c e f o r t h e a d o p t i o n o f l a s e r g l a u c o m a s u r g e r i e s a m o n g t h e p a t i e n t s a s w e l l a s
t h e h e a l t h c a r e p r o fe s s i o n a l s o n a c c o u n t o f t h e s u c c e s s fu l o u t c o m e s o f t h i s p r o c e d u r e .
M u l t i p l e p r o f e s s i o n a l s a r e a l s o p r e s c r i b i n g c o m b i n a t i o n t h e r a p i e s f o r t h e t r e a t m e n t o f g l a u c o m a t h a t i n v o l v e s t h e u s e o f p o l y m e r -
b a s e d c o n ta c t l e n s e s , d r u g - e l u t i n g p u n c t a l p l u g s , i m p l a n t a b l e e x t e n d e d - r e l e a s e d e v i c e s , m i c r o n e e d l e - i n j e c t i o n d e v i c e s a n d m i c r o -
d o s i n g t e c h n o l o g i e s . C o u p l e d w i t h t h e i n c r e a s i n g n u m b e r o f a w a r e n e s s p r o g r a m s c o n d u c t e d b y m u l t i p l e o r g a n i z a t i o n s t o s p r e a d
a w a r e n e s s r e g a r d i n g t h e a v a i l a b i l i t y o f e f f e c t i v e g l a u c o m a t h e r a p e u t i c s , t h i s i s c r e a t i n g a p o s i t i v e o u t l o o k f o r t h e m a r k e t . S o m e
o f t h e o th e r f a c t o r s c o n t r i b u t i n g t o t h e m a r k e t g r o w t h i n c l u d e t h e c o n t i n u a l r e s e a r c h a n d d e v e l o p m e n t ( R & D ) a c t i v i t i e s t o
i n t r o d u c e i n n o v a t i v e t h e r a p e u t i c s a n d t h e i m p r o v i n g h e a l t h c a r e i n f r a s t r u c t u r e a c r o s s t h e g l o b e , e s p e c i a l l y i n d e v e l o p i n g
e c o n o m i e s .
L o o k in g f o r w a r d , t h e m a r k e t i s e x p e c t e d t o g r o w a t a C A G R o f 5 . 6 % d u r in g 2 0 2 4 - 2 0 3 2 .
V ie w R e p o r t T O C , F i g u r e s a n d T a b l e s : h t t p s : / / w w w . i m a r c g r o u p . c o m / g l a u c o m a - t h e r a p e u t i c s - m a r k e t
Breakup by Drug Class:
• Prostaglandin Analogs
• Beta Blockers
• Alpha Adrenergic Agonists
• Carbonic Anhydrase Inhibitors
• Combination Drugs
Report • Others
Segmentation Breakup by Indication:
• Open Angle Glaucoma
• Angle Closure Glaucoma
• Others
Breakup by End User:
• Hospitals
• Ophthalmic Cl inics
• Ambulatory Surgery Centers
• Others
Breakup by Region:
• North America
Report
• Asia-Pacifi c
Segmentation • Europe
• Latin America
• Middle East and Afr ica
• Aerie Pharmaceuticals Inc.
• Allergan Plc
• Bausch & Lomb Incorporated (Bausch
Health Companies Inc.)
Competitive
• Inotek Pharmaceuticals Corp.
Landscape • Merck & Co. Inc.
with Key • Novart is AG
•
Players Pfi zer Inc.
• Santen Pharmaceutical Co. Ltd.
• SIFI S.p.A
• Teva Pharmaceutical Industr ies Ltd
How big is the global glaucoma therapeutics market?
What is the expected growth rate of the global
glaucoma therapeutics market during 2024-2032?
What are the key factors driving the global glaucoma
therapeutics market?
Key
What has been the impact of COVID-19 on the global
glaucoma therapeutics market?
Questions
What is the breakup of the global glaucoma
Answered in therapeutics market based on the drug class?
the Report What is the breakup of the global glaucoma
therapeutics market based on the indication?
What is the breakup of the global glaucoma
therapeutics market based on the end user?
What are the key regions in the global glaucoma
therapeutics market?
Who are the key players/companies in the global
glaucoma therapeutics market?
1 P r e f a c e
2 S c o p e a n d M e t h o d o l o g y
2 . 1 O b j e c t i v e s o f t h e S t u d y
2 . 2 S t a k e h o l d e r s
2 . 3 D a t a S o u r c e s
2 . 3 . 1 P r i m a r y S o u r c e s
2 . 3 . 2 S e c o n d a r y S o u r c e s
2 . 4 M a r k e t E s t i m a t i o n
Table of 2 . 4 . 1 B o t t o m - U p A p p r o a c h 2 . 4 . 2 T o p - D o w n A p p r o a c h
2 . 5 F o r e c a s t i n g M e t h o d o l o g y
3 E x e c u t i v e S u m m a r y
4 I n t r o d u c t i o n
Contents 4 . 1 O v e r v i e w 4 . 2 K e y I n d u s t r y T r e n d s
5 G l o b a l G l a u c o m a T h e r a p e u t i c s M a r k e t
5 . 1 M a r k e t O v e r v i e w
5 . 2 M a r k e t P e r f o r m a n c e
5 . 3 I m p a c t o f C O V I D - 1 9
5 . 4 M a r k e t F o r e c a s t
6 M a r k e t B r e a k u p b y D r u g C l a s s
6 . 1 P r o s t a g l a n d i n A n a l o g s
6 . 1 . 1 M a r k e t T r e n d s
6 . 1 . 2 M a r k e t F o r e c a s t
6 . 2 B e t a B l o c k e r s
6 . 2 . 1 M a r k e t T r e n d s
6 . 2 . 2 M a r k e t F o r e c a s t
6 . 3 A l p h a A d r e n e r g i c A g o n i s t s
6 . 3 . 1 M a r k e t T r e n d s
6 . 3 . 2 M a r k e t F o r e c a s t
6 . 4 C a r b o n i c A n h y d r a s e I n h i b i t o r s
6 . 4 . 1 M a r k e t T r e n d s
6 . 4 . 2 M a r k e t F o r e c a s t
6 . 5 C o m b i n a t i o n D r u g s
6 . 5 . 1 M a r k e t T r e n d s
6 . 5 . 2 M a r k e t F o r e c a s t
6 . 6 O t h e r s
6 . 6 . 1 M a r k e t T r e n d s
6 . 6 . 2 M a r k e t F o r e c a s t
7 M a r k e t B r e a k u p b y I n d i c a t i o n
7 . 1 O p e n A n g l e G l a u c o m a
Table of 7 . 1 . 1 M a r k e t T r e n d s 7 . 1 . 2 M a r k e t F o r e c a s t
7 . 2 A n g l e C l o s u r e G l a u c o m a
7 . 2 . 1 M a r k e t T r e n d s
Contents 7 . 2 . 2 M a r k e t F o r e c a s t
7 . 3 O t h e r s
7 . 3 . 1 M a r k e t T r e n d s
7 . 3 . 2 M a r k e t F o r e c a s t
8 M a r k e t B r e a k u p b y E n d U s e r
8 . 1 H o s p i t a l s
8 . 1 . 1 M a r k e t T r e n d s
8 . 1 . 2 M a r k e t F o r e c a s t
8 . 2 O p h t h a l m i c C l i n i c s
8 . 2 . 1 M a r k e t T r e n d s
8 . 2 . 2 M a r k e t F o r e c a s t
8 . 3 A m b u l a t o r y S u r g e r y C e n t e r s
8 . 3 . 1 M a r k e t T r e n d s
8 . 3 . 2 M a r k e t F o r e c a s t
F o r m o r e i n f o r m a t i o n , v i s i t :
ht t ps : / /w ww. i ma rc gro up . c o m /g l au c o m a- t he ra peut i c s -m a rke t / t
o c
Disclaimer
© 2023 IMARC Al l R ights Reserved
Th is Pub l i ca t ion and a l l i t ’ s con ten ts un less o therw ise men t i oned a re copy r i gh ted in the name o f
I n t e rna t i ona l Marke t Ana lys i s Research and Consu l t ing ( IMARC) . No pa r t o f t h i s pub l i ca t ion may be
rep roduced , repackaged , red i s t r i bu ted o r res o ld i n who le o r i n any pa r t . The pub l i ca t ion may a l so
no t be used i n any f o rm o r by and means g raph i c e lec t ron ic o r mechan ic a l , i nc lud ing pho tocopy ing ,
reco rd ing , t ap ing o r by i n fo rmat i on s to rage o r re t r ieva l , o r by any o the r f o rm, w i t hou t the exp ress
c ons en t o f I n t e rna t iona l Marke t Ana lys i s Research and Consu l t i ng ( IMARC) .
Disc la imer : Al l con ten ts and da ta o f t h i s pub l i c a t i on , i nc lud ing fo recas t s , da ta ana lys i s and op in ion
have been based on in f o rmat ion and sources be l ieved to be accu ra te and re l iab le a t t he t ime o f
pub l i sh ing . In t e rna t i ona l Ma rke t Ana l ys is Research and Consu l t ing makes no rep resen ta t ion o f
war ran t y o f any k ind as to t he acc u racy o r comp le teness o f any I n fo rmat i on p rov ided . IMARC
accep ts no l i ab i l i t y wha tsoever f o r any los s o r damage resu l t i ng f rom op in ion , e r ro rs o r
i naccu rac ies i f any f ound th is pub l i ca t ion .
IMARC, IMARC Group and G loba l Therapy I ns igh t Ser i es a re reg is t e red t rademarks o f I n te rna t iona l
Marke t Ana lys i s Research and Consu l t ing . A l l o the r t rademarks used i n th i s pub l i ca t i on a re
reg i s te red t rademarks o f t he i r r espec t i ve compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145
E-MAIL: [email protected]
Comments